These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 25369821)

  • 1. Aliskiren in an alternate-day administration schedule in hypertensive albuminuric patients.
    Spanos G; Kalaitzidis RG; Karasavvidou DP; Zikou X; Siamopoulos KC
    Blood Press Monit; 2014 Dec; 19(6):359-65. PubMed ID: 25369821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.
    Palatini P; Jung W; Shlyakhto E; Botha J; Bush C; Keefe DL
    J Hum Hypertens; 2010 Feb; 24(2):93-103. PubMed ID: 19458624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained decrease in blood pressure following missed doses of aliskiren or telmisartan: the ASSERTIVE double-blind, randomized study.
    Düsing R; Brunel P; Baek I; Baschiera F
    J Hypertens; 2012 May; 30(5):1029-40. PubMed ID: 22441345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension.
    Verdecchia P; Calvo C; Möckel V; Keeling L; Satlin A
    Blood Press; 2007; 16(6):381-91. PubMed ID: 18058456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria.
    Fogari R; Mugellini A; Zoppi A; Preti P; Maffioli P; Perrone T; Derosa G
    Expert Opin Pharmacother; 2013 Mar; 14(4):371-84. PubMed ID: 23414196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension.
    Puig JG; Schunkert H; Taylor AA; Boye S; Jin J; Keefe DL
    Clin Ther; 2009 Dec; 31(12):2839-50. PubMed ID: 20110023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
    Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
    Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide.
    Schmieder RE; Philipp T; Guerediaga J; Gorostidi M; Smith B; Weissbach N; Maboudian M; Botha J; van Ingen H
    Circulation; 2009 Jan; 119(3):417-25. PubMed ID: 19139391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aliskiren improves blood pressure control and prevents cardiac damage in high-risk hypertensive subjects.
    Mazza A; Montemurro D; Zuin M; Schiavon L; Zorzan S; Chondrogiannis S; Ferretti A; Ramazzina E; Rubello D
    Minerva Cardioangiol; 2013 Aug; 61(4):461-9. PubMed ID: 23846012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.
    Drummond W; Sirenko YM; Ramos E; Baek I; Keefe DL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):327-33. PubMed ID: 21846154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
    Villamil A; Chrysant SG; Calhoun D; Schober B; Hsu H; Matrisciano-Dimichino L; Zhang J
    J Hypertens; 2007 Jan; 25(1):217-26. PubMed ID: 17143194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of aliskiren in Latin America in a real-world setting: aliskiren in Latin America Study (ALAS).
    Volman S; Benitez FN; Cedenio H; Giorgi M; Jaramillo N; Molina N; Zilberman J
    Ther Adv Cardiovasc Dis; 2013 Aug; 7(4):189-96. PubMed ID: 23723254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of aliskiren on blood pressure and humoral factors in hypertensive hemodialysis patients previously on angiotensin II receptor antagonists.
    Ito T; Ishikawa E; Fujimoto N; Okubo S; Ito G; Ichikawa T; Nomura S; Ito M
    Clin Exp Hypertens; 2014; 36(7):497-502. PubMed ID: 24433061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
    Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
    J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of aliskiren/amlodipine combination and high-dose amlodipine monotherapy on endothelial function in elderly hypertensive patients.
    Fukutomi M; Hoshide S; Mizuno H; Kario K
    Am J Hypertens; 2014 Jan; 27(1):14-20. PubMed ID: 24008122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.
    Andersen K; Weinberger MH; Egan B; Constance CM; Ali MA; Jin J; Keefe DL
    J Hypertens; 2008 Mar; 26(3):589-99. PubMed ID: 18300872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease.
    Abe M; Suzuki H; Okada K; Maruyama N; Inoshita A; Baba S; Takashima H; Soma M
    Heart Vessels; 2013 Jul; 28(4):442-52. PubMed ID: 22618635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension.
    Nussberger J; Gradman AH; Schmieder RE; Lins RL; Chiang Y; Prescott MF
    Int J Clin Pract; 2007 Sep; 61(9):1461-8. PubMed ID: 17590217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.